Wegovy Dosage Chart

Wegovy (semaglutide) starts at 0.25 mg once weekly and moves up in steps, each held for at least 4 weeks. At the minimum pace the Product Information allows, the standard maintenance dose of 2.4 mg is reachable at week 17.

If a Wegovy dose is missed, the Product Information says to take it as soon as possible within 5 days of the missed dose. If more than 5 days have passed, skip it and take the next dose on the regular day.

The day of the weekly injection can be changed if necessary, as long as at least 3 days (more than 72 hours) separate two doses.

If you have significant stomach or bowel symptoms, the Product Information says to consider delaying the next step until they improve. If 2.4 mg is not tolerated, the dose can be reduced to 1.7 mg weekly for maintenance, then re-escalated to 2.4 mg if tolerated.

Strengths. Wegovy is registered in five strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg) as a single-dose pen, the four-dose FlexTouch pen and a pre-filled syringe; your pharmacist can tell you which device you have. A 7.2 mg maintenance dose, given as three 2.4 mg injections, is registered for adults with a starting BMI of 30 or more after at least 4 weeks on 2.4 mg.

In Australia, Wegovy is a prescription-only medicine registered for weight management. At the time of writing it is not PBS-subsidised for that use. It is registered as a single-dose pen, the four-dose FlexTouch pen and a pre-filled syringe; your pharmacist can tell you which device you have. Your doctor sets the pace, and the dates on this page are the earliest the Product Information allows each step.

The four-week steps and the 2.4 mg maintenance dose are the same everywhere. The rules around them are worded differently. The Australian Product Information counts the missed-dose window forward from the missed dose (take it within 5 days), where the US label counts back from the next dose (skip it if that is less than 48 hours away); for a weekly dose both come to about 5 days. The Product Information asks for at least 3 days (more than 72 hours) between doses when the injection day moves, where the US label asks for 2. Its side-effect advice is closer to the US label: consider delaying the next step, and drop to 1.7 mg for maintenance if 2.4 mg is not tolerated. Australia also registers three presentations (a single-dose pen, the four-dose FlexTouch pen, and a pre-filled syringe) and a 7.2 mg maintenance dose, given as three 2.4 mg injections, for adults who started with a BMI of 30 or more and have spent at least 4 weeks on 2.4 mg.

If you read a US source, or an AI answer trained on one, check the rules against this page and your own patient leaflet before acting on them.

Wegovy 7.2 mg is a higher maintenance dose, three times the standard 2.4 mg, for adults with obesity. It sits on top of the chart above rather than replacing it: the Product Information allows the step up to 7.2 mg once weekly only after a minimum of 4 weeks on 2.4 mg, and only for adults with a BMI of 30 or more when they started.

In Australia the 7.2 mg dose is registered within the same Product Information as the 2.4 mg pathway (revised 22 June 2026) and is given as three 2.4 mg injections one after another, at least 5 cm apart. It is not a separate product or pen. The 5-day missed-dose window and the 3-day gap when moving your injection day carry over unchanged, and the Product Information says to consider delaying escalation if stomach or bowel symptoms are significant. If body weight does not improve further on 7.2 mg, the Product Information says to go back to 2.4 mg.